BLGO — BioLargo, Inc. Company Overview

Executive Summary

BioLargo, Inc. (OTCQX: BLGO) is a small-cap, Delaware-incorporated cleantech innovator pursuing a diversified portfolio of early-stage technology platforms spanning odor and VOC control, PFAS and industrial water treatment, grid-scale battery energy storage, and medical wound care. For fiscal 2025, the company's auditors issued a going-concern qualification after revenue declined 56% year-over-year — driven by the loss of, and a payment default by, its largest customer, a private-label odor-control partner formerly operating under the "Pooph" brand — pushing the net loss to $15.2 million from $4.3 million in fiscal 2024. BioLargo is best understood as a speculative, multi-platform technology incubator rather than an established operating company, with real intellectual property but limited proven commercial scale.

Core Business Model

BioLargo operates a hybrid model that combines direct product sales in its one material commercial business (odor and VOC control) with capital-efficient minority-stake and joint-venture structures for its more capital-intensive platforms. Its battery storage technology is housed in BETI, a 95%-owned subsidiary, and its medical device business is housed in Clyra Medical, a 48%-owned affiliate — structures that let BioLargo participate in the upside of large, capital-hungry markets (grid storage, medical devices) without funding full commercialization alone, while also diluting its economic claim on any success in those units. A fourth unit, BLEST (70%-owned), provides third-party engineering consulting and generates a recurring revenue stream, including an approximately $100,000-per-month U.S. Air Force base services contract, alongside supporting internal R&D.

Business Segments

Odor & VOC Control is BioLargo's only currently material revenue-generating business, representing 76% of fiscal 2025 revenue, built around its flagship CupriDyne Clean product used at landfills and waste-handling facilities, plus historical private-label pet-odor product sales. Water Treatment encompasses several distinct technologies at different maturity stages: the Aqueous Electrostatic Concentrator (AEC) for removing PFAS ("forever chemicals") from drinking water, which has been installed and is operational in Lake Stockholm, New Jersey; AROS, a minimal-liquid-discharge system co-developed with partner Garratt-Callahan for industrial cooling-tower water recycling; and AOS, an advanced oxidation system for micropollutant removal, whose domestic development has been paused pending clearer U.S. regulatory pathways, with the company now exploring European opportunities instead. Battery Energy Storage is pursued through BETI's "Cellinity" liquid sodium battery technology, targeting grid-scale, long-duration storage applications, currently at prototype/pilot manufacturing stage in Oak Ridge, Tennessee. Medical Products, through Clyra Medical, centers on ViaCLYR, an FDA 510(k)-cleared wound-irrigation solution using a proprietary Copper-Iodine Complex Solution, which received its first purchase order in February 2026.

Product Portfolio

Key named products include CupriDyne Clean (odor/VOC control), the Aqueous Electrostatic Concentrator and AROS (water treatment), Cellinity (sodium battery chemistry), and ViaCLYR (wound irrigation). Each represents a different technology platform and end market, giving BioLargo broad optionality but little concentrated commercial traction in any single high-growth category as of its most recent fiscal year.

Competitive Landscape

BioLargo's 10-K explicitly names competitors in each of its business lines, and in every case the company is a sub-scale entrant against larger, better-resourced incumbents. In odor control, it competes against Weaver Consulting Group, Atmos Technologies, Chemstation, and OMI Industries — established players in a fragmented but mature niche. In battery energy storage, Cellinity would eventually compete against Tesla, CATL, BYD, Panasonic, and LG, a set of the largest and best-capitalized battery manufacturers in the world, in a capital-intensive industry where BioLargo remains pre-commercial. In water treatment, it names Veolia, AECOM, Xylem, and Pentair as competitors — large, diversified infrastructure and water-technology companies with vastly greater engineering, sales, and balance-sheet resources. BioLargo's stated strategy in each vertical relies on differentiated, patented technology rather than scale or cost leadership, which is a reasonable strategy for a company of its size but one that carries substantial execution risk given the resource gap versus incumbents.

Strategic Strengths & Risks

BioLargo's genuine strength is its intellectual property base: 34 issued patents (26 in the U.S.) with an average remaining life of approximately seven years, developed in part through more than 90 government grants that have provided non-dilutive R&D funding over the company's history. The February 2026 FDA clearance and first purchase order for ViaCLYR represents a tangible, near-term commercialization milestone for the medical segment, and the diversified, multi-platform structure provides optionality across several large addressable markets (PFAS remediation, grid-scale storage, wound care) that could each individually be worth multiples of BioLargo's current market capitalization if commercialized successfully.

The risks, however, are severe and immediate. The auditor's going-concern qualification reflects genuinely precarious finances: fiscal 2025 cash used in operations was $8.3 million against only $3.9 million of cash on hand at year-end, and working capital stood at just $51,000, implying the company will need continuous access to dilutive equity financing (it has relied on a Lincoln Park Capital purchase agreement, which expired February 1, 2026, plus direct stock offerings) simply to continue operating. The FY2025 net loss included a $3.9 million credit loss tied to the default of its largest customer, illustrating acute customer-concentration risk in its only material revenue line. The company also carries an outstanding heavily diluted capital structure, with 319.75 million shares outstanding as of March 2026 against an aggregate public float of only about $63.1 million, and is engaged in active patent-infringement litigation against its former largest customer (the "Pooph" entity), consuming management and legal resources. Its OTCQX listing limits institutional investor access and trading liquidity relative to exchange-listed peers.

Financial Overview

Fiscal 2025 revenue fell 56% year-over-year, and net loss widened to $15.2 million from $4.3 million in fiscal 2024, driven substantially by the customer default and associated credit loss plus the underlying revenue decline. Cash used in operations was $8.3 million versus a year-end cash balance of only $3.9 million, and R&D expense was approximately $2.6 million in 2025 (down slightly from $2.9 million in 2024). BioLargo's financing activity during the year included roughly $2.1 million raised through the Lincoln Park Capital facility, a $2.3 million common stock and $2.1 million Series B preferred raise at Clyra Medical, a $425,000 BETI stock sale, and a $215,000 accredited-investor offering — a pattern of frequent, relatively small capital raises characteristic of a cash-constrained micro-cap.

Summary Conclusion

BioLargo is a high-risk, optionality-driven micro-cap whose real patent portfolio and multi-market technology platforms (PFAS remediation, grid-scale battery storage, wound care) remain commercially unproven at meaningful scale, while its only material revenue business suffered a severe, customer-concentration-driven setback in fiscal 2025. With an explicit going-concern qualification, minimal working capital, and dependence on continuous dilutive financing, BLGO today more closely resembles a call option on several nascent technologies than a moat-protected operating franchise.